Noninvasive Biomarker Research Aims to Improve Treatment for Brain Tumors

Glioblastoma multiforme (GBM) remains one of the most challenging forms of malignant brain tumors. This fast-growing central nervous system tumor forms in the supportive tissue of the brain and spinal cord and results in a median patient survival of just 15 months.

With a new T1 pilot grant from UC’s Center for Clinical and Translational Science and Training (CCTST), El Mustapha Bahassi, PhD, hopes to give clinicians a new tool in managing the disease more effectively without invasive measures. CCTST is the academic home of the university’s institutional Clinical and Translational Science Award from the National Institutes of Health.

Bahassi is using whole genome sequencing to identify and then track specific tumor mutations (circulating mutant DNA) through the blood. 

Whole genome sequencing is a laboratory process to determine the complete DNA sequence of a person’s genome (i.e., complete hereditary makeup)—at a single time. Genetic instructions from DNA fuel all biologic developments and functions in the body. 

"Tumors release small fragments of DNA that carry the same genetic information we would get by doing a tissue biopsy in the brain. Gathering this information from the patient through blood samples—before, during and after treatment—could tell us whether the patient is responding to treatment or likely to have a relapse through blood samples and avoid multiple, invasive brain tumor biopsies,” says Bahassi, who is also a research assistant professor in the UC College of Medicine Department of Internal Medicine, Division of Hematology Oncology. 

"Utilizing whole genome sequencing could help identify changes in the genomes of brain tumors that drive cancer progression and aid in the development of noninvasive biomarkers to help follow treatment effectiveness and predict tumor recurrence,” adds Bahassi.    

Basic Scientists and Clinicians Working Together

At the UC Brain Tumor Center, basic scientists and neurosurgeons are working together to tackle the problem in a pre-clinical study using human brain tumor tissue samples. The original study included 10 tumor samples and was funded by UC and small foundation grants from the Mayfield Education & Research Foundation, Shemenski Foundation and LCS/Sahlfeld Foundation

Additional funding from the CTSA has given Bahassi and Warnick resources to collect whole genome sequencing data on an additional 40 patients from the UC Brain Tumor Center to determine if the approach is feasible for a phase-1 clinical trial. 

The UC Brain Tumor Center is one of nine centers of the UC Neuroscience Institute and one of five comprehensive disease-based centers of the UC Cancer Institute. Both institutes are partnerships of UC Health and the UC College of Medicine. Learn more about the UC Brain Tumor Center at ucbraintumorcenter.com.